Covid-19 Update

Neale Hanvey Excerpts

Monday 29th November 2021 Commons Chamber

[Sajid Javid]

I agree absolutely with my right hon. Friend.

[Neale Hanvey (Kirkcaldy and Cowdenbeath) (Alba)]

The emergence of omicron is not really much of a surprise; it is more a case of when, not if. Anecdotal evidence from South Africa suggests that, while it may be more infectious, the potency seems to be more limited. Of particular concern are the mutations to the spike protein in two specific areas, so what action are the Government taking to put in additional resources to adjuvant therapy development, especially given the impact on monoclonal antibody therapies and the vaccine, and what is the status of genomic surveillance in the UK at present?

[Sajid Javid]

First, I think it is fair to say that our genomics surveillance has never been so strong. It was getting stronger even before the pandemic, but because of the pandemic, there has been a huge amount of investment, and it has paid off UK-wide. On the treatments, there is some concern about this new variant and Ronapreve, which is one of the key monoclonal antibodies that we use for treatment, but it is just concern at this point; there is no particular evidence. However, part of the reason for taking these measures is to buy the time we need—two to three weeks—to give our scientists time to assess the risk of this variant properly.